Third Party Withdraws Appeal Related to Cantargia Patent
LUND, SE / ACCESSWIRE / November 20, 2023 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today reported that...
Cancer
MedTech Innovator Crowns MicroTransponder and Mirai Medical Among its Top Innovators of 2023
Revolutionary Medical Device Companies Awarded with Prestigious Mid-Stage Grand Prize and Value Award at the MedTech Strategist Innovation SummitLOS ANGELES--(BUSINESS...
Theralase(R) Commences Non-Brokered Private Placement and Termination of Previously Announced Financing
TORONTO, ON / ACCESSWIRE / November 17, 2023 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage...
University of Wisconsin–Madison and GE HealthCare Broaden Shared Commitment to Healthcare Innovation
The 10-year strategic collaboration builds on strong research foundations in medical imaging and expands the scope to advance the delivery...
Adlai Nortye Announces Completion of Patient Enrollment in Global Phase III Clinical Trial of Buparlisib (AN2025) in Combination with Paclitaxel for the Treatment of Recurrent or Metastatic HNSCC
SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or...
Medicenna Announces Compelling Survival Benefit from Phase 2b Study of Bizaxofusp in Recurrent Glioblastoma at the 28th Annual Meeting of the Society for NeuroOncology
Single treatment of bizaxofusp doubled mOS (14.5 months vs. 7.2 months) irrespective of IL4R expression (high or low) compared to...
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine
Data subsets to be shared today in plenary oral presentations at the 2023 Society for Neuro-Oncology Annual MeetingBRISBANE, Calif., Nov....
Mendus Announces Nomination Committee for the 2024 Annual General Meeting
Press Release Stockholm, Sweden, November 17, 2023 Mendus AB (publ: IMMU.ST) announced today that the members of the Nomination Committee...
Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma
TAIPEI, Taiwan and SAN DIGEO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the...
Precipio Announces Q3-2023 Shareholder Update Call
Conference Call to be held on November 20th, 2023 at 5:00 PM ESTNEW HAVEN, Conn., Nov. 16, 2023 (GLOBE NEWSWIRE)...
Alpha Tau Medical Announces Third Quarter 2023 Financial Results and Provides Corporate Update
- Treated the first patient with advanced inoperable pancreatic cancer at Hadassah Medical Center in Israel in September, alongside safety...
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers
Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer...
Ludwig Enterprises Appoints Scott Silverman as CFO
SPARKS, NV / ACCESSWIRE / November 16, 2023 / Ludwig Enterprises, Inc., the Genomics Language Company™, focused on the development...
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control” Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure diabetesNew...
Poolbeg Pharma PLC Announces POLB 001 LPS Trial Data to be Presented at IUIS
POLB 001 - a potential blockbuster immunomodulatorLONDON, UK / ACCESSWIRE / November 16, 2023 / Poolbeg Pharma (AIM:POLB)(OTCQB:POLBF), 'Poolbeg' or...
Yunu Integration to Florence Improves Imaging Accuracy and Workflow Efficiency
Partnership extends capability for trial imaging integration to Florence Healthcare's 18,000 activated clinical trial sites.ATLANTA, GA / ACCESSWIRE / November...
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment...
StageZero Life Sciences, Ltd Announces Q3 2023 Financial Results and Operational Update
TORONTO, ON / ACCESSWIRE / November 15, 2023 / StageZero Life Sciences ("StageZero" or the "Company") (TSX:SZLS), an integrated healthcare...
Humanetics Corporation Appoints Dr. Colin Chinn as Chief Medical Officer
Dr. Chinn retired as a Rear Admiral of the United States NavyMINNEAPOLIS--(BUSINESS WIRE)--Humanetics Corporation, a leading innovator in medical countermeasures,...
StageZero Life Sciences Partners with My One Medical Source and 1,000+ Medical Access Points in the USA
Aristotle and AVRT to be offered to My One Medical Source's Customer BaseTORONTO, ON / ACCESSWIRE / November 14, 2023...